Through the rights issue, the number of shares and votes in the Company has increased by 538,043,455. Through the set-off issue, the number of shares and votes in the Company has increased by 31,050,000.  Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 1,107,136,910.  For More Information:  Erik Kinnman, Chief Executive Officer  Phone: +46 018-50 54 40  E-mail: IR@vivesto.com  About Vivesto AB  Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.  Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.  This information is information that Vivesto AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-02-27 08:30 CET.  Attachments

New number of shares and votes in Vivesto

KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.  The Board of Directors of Vivesto AB (“Vivesto” or the “Company”) has today, based on the authorisation from the Extraordinary General Meeting held on 22 December 2025, resolved on a directed new issue of 31,050,000 shares to certain guarantors in the rights issue of shares resolved upon by the Board of Directors on 20 November 2025 (the “Rights Issue“), in accordance with the guarantee agreements previously communicated (the “Compensation Issue“). The subscription price in the Compensation Issue is SEK 0.10 per share, and payment is made by offsetting the guarantors' claims on the Company.  In connection with the Rights Issue, the Company received guarantee undertakings from the existing shareholder Arwidsro Investment AB (“ Arwidsro Investment ”) through a so-called top guarantee, as well as from an additional existing shareholder and a number of external investors through so-called bottom guarantees. As communicated in connection with the announcement of the Rights Issue, the guarantors are, according to the guarantee agreements entered into, entitled to commission, whereby commission for the bottom guarantee undertakings is paid with 15 percent of the guaranteed amount in the form of newly issued shares in the Company, or alternatively 13 percent of the guaranteed amount in the form of cash commission. For the top guarantee undertaking provided by Arwidsro Investment, commission is paid with 17 percent of the guaranteed amount, only in the form of newly issued shares in the Company.  In addition to Arwidsro Investment, a number of guarantors have chosen to receive guarantee commission in the form of shares, whereas the others will receive cash guarantee commission. Accordingly, the Board of Directors of Vivesto has today, based on the authorisation from the Extraordinary General Meeting held on 22 December 2025, resolved on the Compensation Issue, comprising 31,050,000 shares to Arwidsro Investment and the bottom guarantors who have chosen to receive guarantee commission in the form of shares. The cash portion of the guarantee commission paid to bottom guarantors who have chosen cash commission amounts to approximately SEK 2.6 million.  The reason for the deviation from the shareholders' preferential rights is to fulfil the Company's obligations to the guarantors, as they under the guarantee agreements entered into are entitled to set off their claims against the Company arising from guarantee undertakings provided in connection with the Rights Issue. In addition, the Board of Directors considers that it is beneficial to the Company's financial position and in the interest of the shareholders to settle the guarantee commission in the form of shares instead of cash payment, as it preserves cash resources, thus strengthening the Company's working capital.  Payment in the Compensation Issue shall be made by set-off of claims against the Company, which consists of these guarantors' entitlement to guarantee commission. The subscription price in the Compensation Issue amounts to SEK 0.10 per share, which corresponds to the subscription price per share in the Rights Issue. The guarantee commission and the subscription price were determined through arm's length negotiations between the Company and the parties that have provided guarantee undertakings in connection with the entry into the guarantee agreements prior to the Board of Directors' resolution to carry out the Rights Issue, which was made in consultation with the Company's financial advisor Bergs Securities. The Board of Directors therefore considers that the terms have been determined in such a way as to ensure market fairness and that they reflect prevailing market conditions.  Through the Compensation Issue, the Company's share capital will increase by SEK 3,105,000, from SEK 107,608,691 to SEK 110,713,691, through a new issue of 31,050,000 shares, which entails that the total number of shares in the Company will increase from 1,076,086,910 to 1,107,136,910, corresponding to a dilutive effect of approximately 2.8 percent of the total number of shares and votes in the Company. The above figures are calculated based on the number of outstanding shares in the Company following registration with the Swedish Companies Registration Office of the Rights Issue.  Advisors  In connection with the Rights Issue, Vivesto has engaged Bergs Securities as financial advisor and Sole Bookrunner. TM & Partners is acting as legal advisor to the Company.  For more information:  Erik Kinnman, Chief Executive Officer, Vivesto  Phone: +46 018-50 54 40  E-mail: IR@vivesto.com  About Vivesto AB  Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.  Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.  Important information  The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Vivesto in any jurisdiction, neither from Vivesto nor from someone else.  This press release is not a prospectus for the purposes of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the ” Prospectus Regulation ”) and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in accordance with Annex IX of the Prospectus Regulation. Each investor is encouraged to make their own assessment of whether it is appropriate to invest in the Company.  This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness.  This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “ Securities Act ”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.  In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of ”investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ” Order ”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ” relevant persons ”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.  Forward-looking statements  This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as ”believe”, ”expect”, ”anticipate”, ”intend”, ”may”, ”plan”, ”estimate”, ”will”, ”should”, ”could”, ”aim” or ”might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.  Attachments

Vivesto carries out a directed share issue to guarantors in connection with the completed rights issue

KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.  The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has prepared and published an information document regarding the Company's new issue of shares with preferential rights for existing shareholders of approximately SEK 53.8 million, which was resolved by the Board of Directors on 20 November 2025 and approved by the Extraordinary General Meeting on 22 December 2025 (the "Rights Issue").  Information document  In connection with the Rights Issue, the Company has prepared an information document (the " Information Document ") in accordance with Article 1.4 db and Article 1.5 ba of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC as amended (the " Prospectus Regulation "). The Information Document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.  Vivesto today announces that the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website, , and on Bergs Securities' website,  The Rights Issue in brief  Each existing share in the Company held on the record date for the Rights Issue entitles to one (1) subscription right. Each subscription right entitles to subscription for one (1) share. This entails that the Rights Issue comprises no more than 538,043,455 new shares.  The subscription price has been set at SEK 0.10 per share, which, provided that the Rights Issue is fully subscribed, corresponds to total issue proceeds of approximately SEK 53.8 million before issue costs.  The subscription period runs from and including 8 January up to and including 22 January 2026.  Subscription rights not exercised during the subscription period will become invalid and lose their value. Trading in subscription rights is planned to take place on Nasdaq Stockholm from and including 8 January 2026 up to and including 19 January 2026.  The record date for participation in the Rights Issue is 5 January 2026. The last day of trading in the Company's shares including the right to receive subscription rights was 30 December 2025. The shares will be traded without the right to receive subscription rights from and including 2 January 2026. Application for subscription for shares may also take place without exercise of subscription rights.  The Company has received subscription commitments from existing shareholders totalling approximately SEK 14.8 million, corresponding to approximately 27.5 percent of the Rights Issue. Furthermore, Arwidsro Investment AB has provided a guarantee undertaking of SEK 15 million through a so-called top guarantee. In addition, an existing shareholder and a number of external investors have provided guarantee undertakings totalling approximately SEK 24.0 million through so-called bottom guarantees. In total, the Rights Issue is fully covered by subscription commitments and guarantee undertakings.  The net proceeds from the Rights Issue are mainly intended to be used to complete the ongoing pilot study with Paccal Vet in dogs, the ongoing dose-determination study in cats, as well as to conduct preclinical trials with Cantrixil and a pilot study with Cantrixil in dogs. Furthermore, up to SEK 15 million is intended to be used to repay loans under the credit facilities entered into with Arwidsro in April and November 2025. In addition, the proceeds are intended to be used for general corporate purposes.  Based on the current cost structure and development plan, Vivesto's assessment is that the proceeds from the Rights Issue will finance the operations into the second half of 2027.  Timetable for the Rights Issue  First day of trading in the share excluding the right to receive subscription rights  2 January 2026  Record date for the Rights Issue  5 January 2026  Trading in subscription rights  8 – 19 January 2026  Subscription period  8 – 22 January 2026  Trading in paid subscribed shares (BTA)  8 January 2026 – around 6 February 2026  Expected date for publication of the outcome of the Rights Issue  23 January 2026  Advisors  In connection with the Rights Issue, Vivesto has engaged Bergs Securities as financial advisor and Sole Bookrunner. TM & Partners is acting as legal advisor to the Company.  For more information:  Erik Kinnman, Chief Executive Officer, Vivesto  Phone: +46 018-50 54 40  E-mail: IR@vivesto.com  About Vivesto AB  Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.  Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.  Important information  The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Vivesto in any jurisdiction, neither from Vivesto nor from someone else.  This press release is not a prospectus for the purposes of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the ” Prospectus Regulation ”) and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in accordance with Annex IX of the Prospectus Regulation. Each investor is encouraged to make their own assessment of whether it is appropriate to invest in the Company.  This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness.  This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the " Securities Act "), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.  In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.  Forward-looking statements  This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.  Attachments

Vivesto publishes information document regarding the rights issue

Michael af Winklerfelt kommer närmast från rollen som finanschef på Fresenius Kabi, enligt sin profilsida på Linkedin. Han har också tidigare innehaft en liknande roll på börsnoterade Xspray Pharma, Prostatype Genomics och Oasmia, samt ledande finansbefattningar inom Atlas Copco-koncernen.  "Vi är glada att välkomna Michael som Boules nya CFO. Hans starka finansiella kompetens och breda erfarenhet inom kommersiella och operativa områden kommer att vara avgörande för att driva Boules globala tillväxt, förbättra lönsamheten och leverera innovation inom decentraliserad bloddiagnostik", säger Torben Nielsen, vd för Boule.  Nuvarande finanschef Holger Lembrér kommer att fortsätta i sin roll tills att Michael af Winklerfelt tar över i februari.  Reno Santic  Nyhetsbyrån Finwire  https://twitter.com/finwire  newsroom@finwire.se

Boule Diagnostics utser ny finanschef

All resolutions were in accordance with the proposals, described in detail in the general meeting documents which are available on the company's website,  Resolution on amendments of the articles of association and on approval of the Board of Directors' resolution on a new issue of shares with preferential rights for existing shareholders  It was resolved to approve the Board of Directors' resolution on 20 November 2025 on a new issue, with preferential rights for existing shareholders, of no more than 538,043,455 shares, entailing an increase in share capital of no more than SEK 53,804,345.5 (the ” Rights Issue ”).  The right to subscribe for shares shall, with preferential rights for existing shareholders, be granted those who on the record date for the new issue on 5 January 2026 are registered as shareholders in the company. Each shareholder receives one (1) subscription right for each (1) share held. Each (1) subscription right entitles to subscription for one (1) share. The subscription price is SEK 0.10 per share. Subscription for shares shall be made during the period from and including 8 January 2026 up to and including 22 January 2026. The Board of Directors is entitled to extend the subscription period.  For the Rights Issue, the detailed terms and conditions set out in the general meeting documents available on the company's website and in the information document that will be published in connection with the Rights Issue shall apply.  The resolution was made in fulfilment of the majority requirement set by the Swedish Securities Council as a condition for the validity of the exemption from the mandatory bid obligation granted to Per Arwidsson and related parties in relation to Arwidsro Investment AB's guarantee undertaking regarding the Rights Issue.  In order to enable the Rights Issue, it was resolved to amend the limits for the share capital and the number of shares in the articles of association.  Resolution on approval of guarantee undertaking  It was resolved to approve the entry into an agreement with Arwidsro Investment AB (“ Arwidsro Investment ”), under which Arwidsro Investment provides a so-called top guarantee undertaking in the Rights Issue (the “ Top Guarantee Undertaking ”). The Top Guarantee Undertaking entails that Arwidsro Investment undertakes to subscribe and pay for shares in the Rights Issue in addition to its pro rata share in the event that the Rights Issue is not fully subscribed with or without exercise of subscription rights, including the subscription commitments and other guarantee undertakings. The amount guaranteed under the Top Guarantee Undertaking amounts to SEK 15 million.  Resolution on authorization for the Board of Directors to resolve on a new issue of shares to guarantors  It was resolved, in order to enable new issue of shares as guarantee commission to the parties that have entered into guarantee undertakings (the “ Guarantors ”) in the Rights Issue, to authorize the Board of Directors to, on one or several occasions during the period up until the next Annual General Meeting, resolve on a new issue of shares to the Guarantors, with deviation from the shareholders' preferential rights. The number of shares that may be issued under the authorization may not exceed the number of shares corresponding to the agreed guarantee commission that the company is to pay to the Guarantors. Payment may be made by set-off, or otherwise with conditions.  Further information on the proposals approved by the Extraordinary General Meeting is set out in the general meeting documents available on the company's website.  For More Information:  Erik Kinnman, Chief Executive Officer  Phone: +46 018-50 54 40  E-mail: IR@vivesto.com  About Vivesto AB  Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.  Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.  Attachments

Report from Extraordinary General Meeting in Vivesto AB

Lonza supports healthcare customers in the commercialization of products in the pharmaceutical, biotech, and nutrition markets. The company offers services combining technological insight with manufacturing, scientific expertise, and process excellence to help deliver medicines. Lonza serves the pharma, biotech, and nutrition sectors of the healthcare industry. It was founded in 1897 and is based in Basel, Switzerland.

Lonza

Oasmia Pharmaceutical AB , an oncology-focused specialty pharmaceutical company , and Lonza , a global development and manufacturing partner to the pharma , biotech and nutrition industries , have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for its investigational drug candidate , Cantrixil .

Oasmia and Lonza Sign Manufacturing Agreement for Ovarian Cancer Drug Candidate

FarmaMondo is a Swiss-based pharmaceutical group specializing in market access services and the distribution of specialty medicines within the healthcare sector. The company provides access to both licensed and unlicensed medicines, focusing on fulfilling unmet medical needs through Named Patient Programs and full commercialization. FarmaMondo primarily serves healthcare providers, hospital pharmacists, and pharmaceutical companies. It was founded in 1915 and is based in Chiasso, Switzerland.

FarmaMondo

Taiba Healthcare is a provider of healthcare services in the pharmaceutical and healthcare industry. The company offers services including the distribution of medications, specialized treatments, preventive care, and health management solutions. Taiba Healthcare serves various sectors within the healthcare industry, focusing on hospital products, niche and rare disease medications, and therapeutic segments such as oncology, endocrinology, and cardiology. It was founded in 1997 and is based in Oman.

taiba

Elevar Therapeutics is a biopharmaceutical company focused on developing oncology therapeutics. The company aims to provide treatment options for patients with limited or inadequate therapeutic options by advancing next-generation therapies. Elevar Therapeutics identifies and evolves medicines to address the needs of patients, caregivers, and healthcare providers in a range of therapeutic areas. It is based in Salt Lake City, Utah.

Elevar Therapeutics

Karo Healthcare offers a variety of over-the-counter products and prescription medicines that are relevant to health-related issues encountered in daily life. Karo Healthcare serves the pharmacy, retail, and healthcare provider sectors with its health products. Karo Healthcare was formerly known as Karo Pharma. It was founded in 1987 and is based in Stockholm, Sweden.

Karo Healthcare

TitanX

Dynapac

Atlas Copco

Oasmia Pharmaceuticals is a drug development company operating within the pharmaceutical industry. The company specializes in creating treatment options for cancers, utilizing its proprietary drug delivery platform. Oasmia Pharmaceuticals offers products including Cantrixil for blood cancer and Paccal Vet for veterinary oncology, which are currently in various stages of clinical trials. It is based in Uppsala, Sweden.

Date	10/23/2015
Round	IPO
Amount	$9.25M
Investors	Public
Valuation	$XXM
Revenue	0 FY undefined
Sources	1

How VCs Use CB Insights

Professional Services

Platform Overview

Oasmia Pharmaceuticals

Funding, Valuation & Revenue